Literature DB >> 26379889

Value of sequential 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) in prediction of the overall survival of esophageal cancer patients treated with chemoradiotherapy.

Yimin Li1, Qin Lin1, Zuoming Luo2, Long Zhao2, Luchao Zhu1, Long Sun2, Hua Wu2.   

Abstract

This study is to investigate the value of the metabolic parameters measured by sequential FDG PET/CT in predicting the overall survival of patients with esophageal squamous cell carcinoma (ESCC). A total of 160 patients who were newly diagnosed as ESCC patients and treated with chemoradiotherapy were included in this study. The FDG PET/CT was carried out prior to radiotherapy (PET1), when the cumulative dose of radiotherapy reached 50 Gy (PET2), at the end of radiotherapy (PET3) and 1 month after radiotherapy (PET4). The max of the standard uptake value (SUVmax) of the primary tumor, the metabolic tumor volume (MTV) and the total lesion glycolisis (TLG) prior to treatment were measured. The correlation of the measured parameters and the derived parameters of SUVmax with the overall survival was analyzed. The relatively reduced percentage of the SUVmax of PET3 and PET4 to the SUVmax of PET1 and PET2, had predictive value for the overall survival. The area under researcher operation curve (ROC) was between 0.62 and 0.73 (P < 0.01). The MTV and TLG prior to treatment might be used to predict the overall survival, and the area under ROC were both 0.69 (P < 0.001). Sequential FDG PET/CT scanning is useful to predict the overall survival of chemoradiotherapy for ESCC. The metabolic parameters and the derived parameters of FDG PET/CT have predictive values for overall survival.

Entities:  

Keywords:  Esophageal cancer; FDG PET/CT; survival analysis

Year:  2015        PMID: 26379889      PMCID: PMC4565272     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  19 in total

1.  Outcomes of patients with esophageal cancer staged with [¹⁸F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection?

Authors:  Arta Monir Monjazeb; Greg Riedlinger; Mebea Aklilu; Kim R Geisinger; Girish Mishra; Scott Isom; Paige Clark; Edward A Levine; A William Blackstock
Journal:  J Clin Oncol       Date:  2010-09-27       Impact factor: 44.544

2.  Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma.

Authors:  P Flamen; A Lerut; E Van Cutsem; W De Wever; M Peeters; S Stroobants; P Dupont; G Bormans; M Hiele; P De Leyn; D Van Raemdonck; W Coosemans; N Ectors; K Haustermans; L Mortelmans
Journal:  J Clin Oncol       Date:  2000-09-15       Impact factor: 44.544

3.  [18F]-Fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemoradiation in esophageal cancer.

Authors:  Daniel Vallböhmer; Arnulf H Hölscher; Markus Dietlein; Elfriede Bollschweiler; Stephan E Baldus; Stefan P Mönig; Ralf Metzger; Harald Schicha; Matthias Schmidt
Journal:  Ann Surg       Date:  2009-12       Impact factor: 12.969

Review 4.  PET monitoring of therapy response in head and neck squamous cell carcinoma.

Authors:  Heiko Schöder; Matthew Fury; Nancy Lee; Dennis Kraus
Journal:  J Nucl Med       Date:  2009-04-20       Impact factor: 10.057

5.  Adenocarcinomas of the esophagus: response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET-CT. Comparison to histopathologic and clinical response evaluation.

Authors:  Johannes B Roedl; Rivka R Colen; Nagaraj S Holalkere; Alan J Fischman; Noah C Choi; Michael A Blake
Journal:  Radiother Oncol       Date:  2008-08-11       Impact factor: 6.280

6.  Mean and maximum standardized uptake values in [18F]FDG-PET for assessment of histopathological response in oesophageal squamous cell carcinoma or adenocarcinoma after radiochemotherapy.

Authors:  Matthias Schmidt; Elfriede Bollschweiler; Markus Dietlein; Stefan P Mönig; Carsten Kobe; Daniel Vallböhmer; Daniel Vallboehmer; Wolfgang Eschner; Arnulf Hölscher; Harald Schicha
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-12-19       Impact factor: 9.236

7.  Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma.

Authors:  Seung Hyup Hyun; Joon Young Choi; Young Mog Shim; Kwhanmien Kim; Su Jin Lee; Young Seok Cho; Ji Young Lee; Kyung-Han Lee; Byung-Tae Kim
Journal:  Ann Surg Oncol       Date:  2009-10-14       Impact factor: 5.344

8.  The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma.

Authors:  Heta Javeri; Lianchun Xiao; Eric Rohren; Jeffrey H Lee; Zhongxing Liao; Wayne Hofstetter; Dipen Maru; Manoop S Bhutani; Stephen G Swisher; Homer Macapinlac; Xuemei Wang; Jaffer A Ajani
Journal:  Cancer       Date:  2009-11-15       Impact factor: 6.860

9.  PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.

Authors:  Florian Lordick; Katja Ott; Bernd-Joachim Krause; Wolfgang A Weber; Karen Becker; Hubert J Stein; Sylvie Lorenzen; Tibor Schuster; Hinrich Wieder; Ken Herrmann; Rainer Bredenkamp; Heinz Höfler; Ulrich Fink; Christian Peschel; Markus Schwaiger; Jörg R Siewert
Journal:  Lancet Oncol       Date:  2007-09       Impact factor: 41.316

10.  A pilot study of [18F]fluorodeoxyglucose positron emission tomography scans during and after radiation-based therapy in patients with non small-cell lung cancer.

Authors:  Feng-Ming Spring Kong; Kirk A Frey; Leslie E Quint; Randall K Ten Haken; James A Hayman; Marc Kessler; Indrin J Chetty; Daniel Normolle; Avraham Eisbruch; Theodore S Lawrence
Journal:  J Clin Oncol       Date:  2007-07-20       Impact factor: 44.544

View more
  7 in total

1.  A study about different findings of PET-CT between neoadjuvant and non-neoadjuvant therapy: SUVmax is not a reliable predictor of lymphatic involvement after neoadjuvant therapy for esophageal cancer.

Authors:  Jae Kil Park; Jae Jun Kim; Seok Whan Moon
Journal:  J Thorac Dis       Date:  2016-05       Impact factor: 2.895

2.  PET/CT-Based Response Evaluation in Cancer-a Systematic Review of Design Issues.

Authors:  Oke Gerke; Karen Ehlers; Edith Motschall; Poul Flemming Høilund-Carlsen; Werner Vach
Journal:  Mol Imaging Biol       Date:  2020-02       Impact factor: 3.488

3.  Confirmation of the prognostic value of pretherapeutic tumor SUR and MTV in patients with esophageal squamous cell carcinoma.

Authors:  Frank Hofheinz; Yimin Li; Ingo G Steffen; Qin Lin; Chen Lili; Wu Hua; Jörg van den Hoff; Sebastian Zschaeck
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-04-04       Impact factor: 9.236

4.  Increased evidence for the prognostic value of FDG uptake on late-treatment PET in non-tumour-affected oesophagus in irradiated patients with oesophageal carcinoma.

Authors:  Yimin Li; Frank Hofheinz; Christian Furth; Chen Lili; Wu Hua; Pirus Ghadjar; Sebastian Zschaeck
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-04-21       Impact factor: 9.236

5.  The relationship between FDG PET/CT-defined metabolic parameters and the histopathological subtype of oesophageal carcinomas.

Authors:  Ulku Korkmaz; Muhammet Bekir Hacioglu; Osman Kostek; Necdet Sut; Hilmi Kodaz; Bulent Erdogan; Funda Ustun; Mert Saynak; Ebru Tastekin; Irfan Cicin; Gulay Durmus-Altun
Journal:  Pol J Radiol       Date:  2020-05-15

6.  Sub-region based radiomics analysis for survival prediction in oesophageal tumours treated by definitive concurrent chemoradiotherapy.

Authors:  Congying Xie; Pengfei Yang; Xuebang Zhang; Lei Xu; Xiaoju Wang; Xiadong Li; Luhan Zhang; Ruifei Xie; Ling Yang; Zhao Jing; Hongfang Zhang; Lingyu Ding; Yu Kuang; Tianye Niu; Shixiu Wu
Journal:  EBioMedicine       Date:  2019-05-23       Impact factor: 8.143

7.  A FDG-PET radiomics signature detects esophageal squamous cell carcinoma patients who do not benefit from chemoradiation.

Authors:  Yimin Li; Marcus Beck; Tom Päßler; Chen Lili; Wu Hua; Ha Dong Mai; Holger Amthauer; Matthias Biebl; Peter C Thuss-Patience; Jasmin Berger; Carmen Stromberger; Ingeborg Tinhofer; Jochen Kruppa; Volker Budach; Frank Hofheinz; Qin Lin; Sebastian Zschaeck
Journal:  Sci Rep       Date:  2020-10-19       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.